H.C. Wainwright lowered the firm’s price target on X4 Pharmaceuticals to $3 from $5 and keeps a Buy rating on the shares post the Q4 results. The firm cries additional dilution as a result of the equity offering for the target drop.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on XFOR:
- X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2022 Financial Results and Provides Corporate Update
- X4 Pharmaceuticals reports Q4 EPS (29c), consensus (24c)
- X4 Pharmaceuticals says held about 2.5% of cash deposits at SVB
- X4 Pharmaceuticals to Report Fourth-Quarter and Full-Year 2022 Financial Results and Host a Conference Call and Webcast on March 21, 2023
- X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)